Molecular targeted therapy for locally advanced/metastatic thyroid carcinoma
10.19538/j.cjps.issn1005-2208.2019.03.05
- Author:
Wei-wei YANG
1
;
Jing-tai ZHI
;
Xiang-qian ZHENG
Author Information
1. Department of Otolaryngology Head and Neck Surgery, Tianjin First Center Hospital Tianjin 300060, China
- Publication Type:Journal Article
- Keywords:
thyroid carcinoma;
molecular targeted therapy;
tyrosine kinase inhibitors
- From:
Chinese Journal of Practical Surgery
2019;39(03):209-212
- CountryChina
- Language:Chinese
-
Abstract:
There is still a lack of effective treatment for radioactive iodine-refractory DTC(RAIR DTC),anaplastic thyroid cancer(ATC)and medullary thyroid cancer(MTC).Once recurrence and metastasis occur,the patient's life is seriously threatened. With the vigorous development of molecular biology of thyroid cancer,many effective molecular targets have been found. Based on one or more targets,molecular targeted drugs underwent clinical trials for the treatment of thyroid cancer,showing good development and application prospects. Sorafenib,vandetanib,lenvatinib and cabozantinib have been approved by FDA for the treatment of advanced thyroid carcinoma. Other molecular targeting inhibitors,such as axitinib and selumetinib,have passed phaseⅡ/Ⅲ clinical trials. The emergence of the drugs provides new choices for the treatment of advanced thyroid cancer and advanced MTC. The drugs have many advantages,such as strong specificity,less side effects and good curative effect,having broad prospects in the treatment of thyroid cancer.
